Dr. Pedapati specializes in the treatment of neuropsychiatric disease associated with ASD, genetic and other neurodevelopmental disorders including interdisciplinary treatment planning and advanced medication management. Prior to his faculty appointment, he had clinical and research training under Craig Erickson, MD, and pediatric transcranial magnetic stimulation under Donald Gilbert, MD, MS.
In 2013, the PI was successful in designing and obtaining IRB approval and competitive funding for a TMS project through the American Academy of Child & Adolescent Psychiatry Pilot Research Award and currently completing the study, "Cortical Plasticity in Adolescent Depression" which attempts to use TMS to determine whether abnormal neuroplasticity can be quantified in adolescent depression.
In his final year of residency, he applied and secured a highly competitive institutional mentor career development award (Procter Scholar) to support 90% time dedicated to independent research activities including obtaining preliminary data on TMS measures of cortical plasticity in ASD and the development of an implicit false belief task of social cognition for future TMS modulation. In addition he continues to be an active subinvestigator extensively contributing to NIH R01 project examining TMS measures of motor physiology in ADHD pioneered the use of SICI as a biomarker in ADHD and measurement of cortical plasticity in healthy youth.
MD: University of Massachusetts, Worcester, MA, 2009.
Residency: Pediatrics/Adult Psychiatry/Child Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, American Board of Pediatrics.
Neurodevelopmental disorders; autism spectrum disorders; fragile X; genetic disorders; schizophrenia
Neurology, Psychiatry, Tuberous Sclerosis
Transcranial magnetic stimulation; transcranial direct current stimulation; TMS; TDCS; EEG; autism; fragile x; eye tracking; electrophysiology.
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Impaired perceptual learning in a mouse model of Fragile X syndrome is mediated by parvalbumin neuron dysfunction and is reversible. Nature Neuroscience. 2018; 21:1404-1411.
Neuropsychiatric feature-based subgrouping reveals neural sensory processing spectrum in female FMR1 premutation carriers: A pilot study. Frontiers in Integrative Neuroscience. 2023; 17:898215.
Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome. Molecular Autism. 2022; 13:47.
Hemispheric Utilization of Alpha Oscillatory Dynamics as a Unique Biomarker of Neural Compensation in Females with Fragile X Syndrome. ACS Chemical Neuroscience. 2022; 13:3389-3402.
Brief Report: Telehealth Satisfaction Among Caregivers of Pediatric and Adult Psychology and Psychiatry Patients with Intellectual and Developmental Disability in the Wake of Covid-19. Journal of Autism and Developmental Disorders. 2022; 52:5253-5265.
Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2022; 14:52.
Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome. Communications Biology. 2022; 5:442.
THALAMOCORTICAL DYSRHYTHMIA AS A UNIFYING MODEL OF NEUROPSYCHIATRIC AND NEUROSENSORY DYSFUNCTION IN FRAGILE X SYNDROME. Journal of the American Academy of Child and Adolescent Psychiatry. 2022; 61:s275-s276.
82.1 Case Studies in Precision Medicine in Syndromic Intellectual Development Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2022; 61:s114.
Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nature Genetics. 2022; 54:1305-1319.